$IFRX News

Last published 5d ago

5d agoIFRXInflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanGlobeNewswireIzicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well...
5d agoIFRXInflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanGlobeNewswireIzicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluatedFindings
1w agoIFRXInflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets DayGlobeNewswireWith a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data
2w agoIFRXInflaRx Announces November Investor EventsGlobeNewswireJena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events
2w agoIFRXInflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026GlobeNewswireData from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22,
1mo agoIFRXInflaRx to Host Virtual Capital Markets DayGlobeNewswireEvent to be hosted on November 3, 2026 at 8:00 AM ESTFeatured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a
2mo agoIFRXInflaRx Announces Participation in September Investor ConferencesGlobeNewswireJena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will
3mo agoIFRXInflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected MilestonesGlobeNewswireAnnounced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported
3mo agoIFRXInflaRx to Report Second Quarter 2026 Results on August 6, 2026GlobeNewswireJena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
4mo agoIFRXInflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on TavneosGlobeNewswireInflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient development plan to
6mo agoIFRXInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesGlobeNewswireJena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that
6mo agoIFRXInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesGlobeNewswireJena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the
6mo agoIFRXInflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal DiseasesGlobeNewswireInflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day highlighting the
6mo agoIFRXInflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver MicrosomesGlobeNewswireJENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical
6mo agoIFRXInflaRx to Report First Quarter 2026 Results on May 7, 2026GlobeNewswireJENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
6mo agoIFRXInflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireJENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced
7mo agoIFRXInflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR InhibitorGlobeNewswireJENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro
7mo agoIFRXInflaRx Announces Participation in the Raymond James 2026 Biotech Innovation SymposiumGlobeNewswireJENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will
7mo agoIFRXInflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual MeetingGlobeNewswireJena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from
8mo agoIFRXInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireJENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has
8mo agoIFRXInflaRx Announces Participation in the Leerink Partners Global Healthcare ConferenceGlobeNewswireJENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate
9mo agoIFRXInflaRx Announces Participation in February Investor ConferencesGlobeNewswireJENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate
10mo agoIFRXInflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value CreationGlobeNewswireInflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in additional I&I
10mo agoIFRXInflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma GangrenosumGlobeNewswireWhile the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc
11mo agoIFRXInflaRx Announces International Nonproprietary Name of "Izicopan" for INF904GlobeNewswireJENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World
1y agoIFRXInflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)GlobeNewswirePhase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concernIn HS, over 4 weeks of
1y agoIFRXInflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous UrticariaGlobeNewswireCompany expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CETCompany also expects to publish third quarter 2025 financial results on the same day pre-market JENA,
1y agoIFRXInflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceGlobeNewswireJENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation
1y agoIFRXInflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireJENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced
1y agoIFRXInflaRx Announces Participation in September Investor ConferencesGlobeNewswireJENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate
1y agoIFRXInflaRx Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireINF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for
1y agoIFRXInflaRx to Report Second Quarter 2025 Results on August 7, 2025GlobeNewswireJENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
1y agoIFRXInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireJENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has
1y agoIFRXInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumGlobeNewswireJENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent
1y agoIFRXInflaRx to Participate in Upcoming Investor ConferencesGlobeNewswireJENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
1y agoIFRXInflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially
1y agoIFRXInflaRx to Report First Quarter 2025 Results on May 7, 2025GlobeNewswireJENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will
1y agoIFRXInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesGlobeNewswireReceived European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab
1y agoIFRXInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingGlobeNewswireJENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of
1y agoIFRXInflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingGlobeNewswireJENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all
1y agoIFRXInflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor ConferencesGlobeNewswireJENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
1y agoIFRXInflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireJENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that
1y agoIFRXInfinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform FinanceACCESS NewswireThe revolutionary blockchain ecosystem from Infinitum, powered by Lusis-global leader in financial systems-sets a new standard in security, resilience, and interoperability, bridging traditional and decentralized finance
1y agoIFRXInflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireJENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the
1y agoIFRXInflaRx Announces Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireJENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that
1y agoIFRXInflaRx Announces Participation in Guggenheim SMID Cap Biotech ConferenceGlobeNewswireJENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will
1y agoIFRXInflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)GlobeNewswireJENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European
1y agoIFRXInflaRx Announces Participation in January Events in San FranciscoGlobeNewswireJENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company
1y agoIFRXInflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904GlobeNewswireJENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first
1y agoIFRXInflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeGlobeNewswireJENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee